Tag: Binnopharm

Binnopharm is a pharmaceutical company that operates two advanced GMP-compliant pharmaceutical plants. Binnopharm produces six dosage forms: ampoules, syringes, aerosols, pills, capsules and solutions. Binnopharm develops and manufactures drugs for the treatment of socially important diseases (respiratory diseases, pulmonology, neurology, nephrology, infectious diseases). Company comprises one of the largest full-cycle biopharmaceutical facilities in Russia with an area of 32,000 sq m; LLC Alium, a modern plant producing infusion solutions; and Binnopharm Distribution an in-house distributor of medicines produced both by Binnopharm/Alium and by third parties.
Company is developing original combinations, biosimilar drugs and unique medications belonging to different treatment groups: pulmonology, neurology, cardiology, gastroenterology and endocrinology. Binnopharm has the largest GMP facilities in Russia for the production of vaccines in ampoules (up to 80m ampoules per year) and a unique, fully equipped quality control laboratory. Over the past seven years, Binnopharm has been covering the bulk of the Russian state’s demand for Hepatitis B vaccine.
The company employs over 300 people, including an R&D group and a marketing and sales team, which were formed in 2015-2016.

Andrey Belashov appointed as CEO of Alium

Sistema PJSFC, a publicly traded diversified Russian holding company, announces that the Board of Directors of its portfolio company Alium Group resolved to appoint Andrey Belashov as its Chief Execut...

Sistema Completed Merger of OBL Pharm and JSC Binnopharm

Sistema PJSFC, a publicly traded diversified Russian holding company, announces the completion of the merger of pharmaceutical assets JSC Pharmaceutical Enterprise Obolenskoe (“OBL Pharm”) and JSC Bin...

Combined Company Based on Obolenskoye-Binnopharm to Work Under Alium Brand

The combined company based on JSC FP Obolenskoye and JSC Binnopharm will work under the new brand, Alium. The step-by-step switch to the new brand will start in May 2019, the group said in a press rel...

RCIF and AFK Sistema invest 19 billion rubles in ‘Obolenskoye’ pharma holding

The Russia-China Investment Fund (RCIF) and AFK Sistema have agreed to establish a leading pharmaceutical company in Russia with a total investment of over 19 billion rubles.

Binnopharm can have tax benefits after receiving the status of industrial complex

30 industrial complexes and 31 industrial parks employing 79.6 thousand persons operate today in Moscow.

Binnopharm production facilities acquired the status of industrial complex

This will allow the company to receive tax preferences and other benefits, including reduced rates of profit tax, preferential rate of land lease and others.

Binnopharm and Biocom to receive loans from Russian Industrial Development Fund

Binnopharm will manufacture AERUS, an antiretroviral OTC drug in aerosol form, in Zelenograd

Nacimbio and Binnopharm will jointly develop and manufacture medicinal products

National Immunobiological Company, a part of Rostec Corporation, and Binnopharm, a Russian full-cycle pharmaceutical company owned by AFK Sistema, signed an agreement on cooperation

Binnopharm has become the exclusive representative of the German MEDICE

JSC Binnopharm, a Russian full-cycle pharmaceutical company, owned by AFK Sistema, has signed a licensing agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG, ranked among top 15 German manufa...

JSC Binnopharm announces the acquisition of 100% stake of Alpharm LLC

JSC Binnopharm, a Russian full-cycle pharmaceutical company owned by AFK Sistema announces signing an agreement for purchase of 100 % of shares of Alpharm LLC and entering the market of OTC drugs. ...

Binnopharm industrial complex obtained ISO 9001:2015 certificate

ISO 9001
The industrial complex Binnopharm has been certified for compliance with the latest version of GOST R ISO 9001: 2015 "Quality Management Systems. Requirements”. This GOST, which entered into force ...